News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2013

Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

02.10.2013 | 131002_press_release_Epigenomics_AG_Polymedco Companies to join efforts in commercialization of Epi proColon® Epigenomics to provide manufacturing, medical, regulatory and strategic marketing Polymedco, the US leader in CRC screening products, to contribute logistics, sales, marketing and customer support

Read more

Ad hoc: Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

PDF 37 KB   Berlin, Germany– Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into a joint commercialization agreement with Polymedco Inc. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America. Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force […]

Read more

Epigenomics AG issues EUR 500,000 in convertible bonds to YA Global Master SPV Ltd.

PDF 84 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces that upon registration of the conditional capital of the Company today successfully completed the issuance of convertible bonds with a nominal amount of EUR 500,000. These convertible bonds constitute the first tranche of a total issuance of up to EUR 5m […]

Read more

Epigenomics AG secures financing of up to EUR 5m

19.08.2013 | 130819_press_release_Epigenomics_AG_financing Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced that it has entered into an agreement with YA Global Master SPV Ltd. (“Yorkville”) through which it secured a convertible bond financing for up to EUR 5m. Under the terms of the […]

Read more

Ad hoc: Epigenomics AG secures financing of up to EUR 5m

PDF 80 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into an agreement with YA Global Master SPV Ltd. through which it secured a convertible bond financing for up to EUR 5m. Under the terms of the agreement, YA Global Master SPV Ltd., over a period of up to […]

Read more

Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights

07.08.2013 | 130807_Press_release_Epigenomics_AG_H1_results Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.

Read more